Sign up USA
Proactive Investors - Run By Investors For Investors

ImpediMed enrols first patient in chronic heart failure trial

The company is planning its European launch in calendar year 2017
Hospital
Heart failure currently costs the U.S. circa US$31bn per year

ImpediMed Ltd (ASX:IPD) has enrolled the first patient in its initial chronic heart failure (CHF) trial using the company’s “SOZO” device.

SOZO uses bioimpedance spectroscopy (BIS) technology to manage and monitor a person’s fluid status, body composition and hydration in a clinical or at-home setting.

This initial study will monitor up to 30 patients with chronic heart failure in a clinical setting for 30 days, and is expected to be completed in the calendar year 2017.

READ: ImpediMed begins lymphoedema study using its health device

If successful, SOZO is expected to provide an early warning system for cardiac decompensation with the potential to optimise patient care and significantly reduce hospital readmissions.

The real-world data generated will be used to form the basis for the design of a larger scale trial expected to be initiated by late 2017.

CHF is among the most expensive diseases in the U.S with an estimated 6.5 mln people suffering from heart failure, with more than 850,000 new patients diagnosed each year.

Heart failure currently costs the U.S. circa US$31bn per year, and is estimated to increase to US$70bn by 2030.

The company obtained CE (European Conformity) mark for SOZO in June 2017 and plans to initiate the European launch of SOZO in key commercial sites in calendar year 2017.

View full IPD profile View Profile

ImpediMed Timeline

Newswire
November 13 2013

Related Articles

woman at a microscope
September 04 2017
Lead product Lojuxta generated revenues of €5.75mln in the first-half
researcher using microscope
September 28 2017
A total of £6mln is expected to come via a share placing and up to a further £2mln through an open offer of stock to existing investors
Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use